[{"orgOrder":0,"company":"Servier","sponsor":"Cellectis","pharmaFlowCategory":"D","amount":"$437.6 million","upfrontCash":"$27.6 million","newsHeadline":"Cellectis and Servier Expand Collaboration on UCART19 Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Servier","sponsor":"Oncodesign","pharmaFlowCategory":"D","amount":"$363.3 million","upfrontCash":"$3.3 million","newsHeadline":"Oncodesign and Servier Reach a Key First Milestone","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Servier Canada","sponsor":"Cellectis","pharmaFlowCategory":"D","amount":"$410.0 million ","upfrontCash":"$27.6 million","newsHeadline":"Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Servier","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"D","amount":"$21.4 million","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Servier Canada","sponsor":"Symphogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Servier Agrees to Buy Symphogen to Swell its Cancer Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Servier","sponsor":"Symphogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Servier Completes the Acquisition of Symphogen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Servier","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences and Servier Expand CART Oncology Development Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Servier","sponsor":"Celsius Therapeutics","pharmaFlowCategory":"D","amount":"$700.0 million","upfrontCash":"Undisclosed","newsHeadline":"Servier and Celsius Therapeutics Announce Target Discovery Collaboration in Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Servier","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$1,800.0 million","newsHeadline":"Servier to Acquire Agios Pharmaceuticals\u2019 Oncology Business","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Servier","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Oncology and Servier To Present Data on LONSURF\u00aeat 2021 ASCO Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Servier","sponsor":"Mina Therapeutics","pharmaFlowCategory":"D","amount":"$262.2 million","upfrontCash":"Undisclosed","newsHeadline":"Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Servier","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$1,800.0 million","newsHeadline":"Servier Completes Acquisition of Agios Pharmaceuticals\u2019 Oncology Business","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Servier","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"$1.25 million","newsHeadline":"Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier Presents Updated Translational Data from Perioperative Study of Vorasidenib and TIBSOVO in Patients with IDH Mutant Low-Grade Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier Report Positive Data from Phase 3 Study of TIBSOVO Azacitidine Combo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO\u00ae (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 AGILE Data of TIBSOVO\u00ae (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Servier","sponsor":"GNS healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Servier","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Servier","sponsor":"Oncodesign","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Servier Collaborates in The Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Servier","sponsor":"Onco360","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TIBSOVO\u00ae (ivosidenib) Now Available from Onco360 for the Treatment of Adult Patients with IDH1-Mutant Acute Myeloid Leukemia or Previously Treated, IDH1-Mutant Metastatic Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Servier","sponsor":"Mission Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier Leverages Mission Bio's Tapestri\u00ae Platform to Uncover AML Resistance Mechanisms in Pivotal TIBSOVO\u00ae (ivosidenib) Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data at ASH 2022 Bolster Servier's Leadership in Hematology Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Servier","sponsor":"Aqemia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Servier and Aqemia Extend Collaboration on Undruggable Target in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Servier","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier and Taiho Oncology Present Overall Survival Data for Trifluridine\/Tipiracil (Lonsurf\u00ae) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier Receives a Positive CHMP Opinion For Tibsovo\u00ae in IDH1-Mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier's Pivotal Phase 3 INDIGO Trial Investigating Vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier Receives European Commission Approval of Tibsovo\u00ae (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Servier","sponsor":"Aitia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aitia Enters into Multi-Year AI-Driven Drug Discovery and Drug Simulation Collaboration with Servier for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"}]
Find Clinical Drug Pipeline Developments & Deals by Servier
Aitia and Servier will focus to discover, validate, and strive to develop novel drug targets and candidates in pancreatic cancer by utilizating Aitia's Pancreatic Cancer Digital Twins and Servier's pre-clinical assays, therapeutic creation platforms, and expertise.
Tibsovo® (ivosidenib tablets) is the first and only IDH1 inhibitor approved in Europe. It has received orphan medicine designation recognizing the significant benefit brought to patients by Tibsovo® over available therapies for both CCA and AML.
AG-881 (vorasidenib) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes. It is beinf developed for the treament of IDH-mutant low-grade glioma.
Tibsovo (ivosidenib) is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. In patients with AML, susceptible IDH1 mutations are defined as those leading to increased levels of 2-hydroxyglutarate (2-HG) in the leukemia cells.
Lonsurf is an oral nucleoside antitumor agent which consists trifluridine, and tipiracil (TP inhibitor), which increases trifluridine exposure by inhibiting its metabolism by TP. Trifluridine results in DNA dysfunction and inhibition of cell proliferation.
Aqemia has employed its unique quantum-physics-inspired artificial intelligence technology to identify innovative, patentable molecules that are experimentally active on an undruggable target in immuno-oncology.
TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with Newly Diagnosed Acute Myeloid Leukemia (AML) susceptible IDH1 mutation.
Under the terms of the agreement, Servier and OPM (through its OncoSNIPE program®) will be responsible for clinical research activities. Servier will fund the associated research costs. The target identification program will be funded by OPM and Servier.
TIBSOVO® (ivosidenib), which is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with newly diagnosed acute myeloid leukemia (AML).
Through this collaboration, Servier has worked with Mission Bio’s Pharma Assay Development services to utilize Tapestri single-cell DNA sequencing technology to serially assess hundreds of samples with IDH1-mutated AML who have been treated with TIBSOVO (ivosidenib).
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
